Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
NLSP similar filings
- 11 May 22 Report of Foreign Private Issuer
- 4 May 22 NLS Pharmaceutics Achieves 90% Enrollment Milestone in Quilience® Phase 2a Clinical Trial for Patients with Narcolepsy
- 27 Apr 22 NLS Pharmaceutics Ltd. Announces Closing of US$4.4 Million Registered Direct Offering
- 25 Apr 22 Report of Foreign Private Issuer
- 14 Apr 22 NLS Pharmaceutics Ltd. Announces US$4.4 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
- 6 Apr 22 Investor Presentation | April 2022 Alexander Zwyer, CEO & Co - Founder defining Central Nervous System Therapies
- 1 Apr 22 NLS Pharmaceutics Announces Receipt of Notice of Deficiency with Nasdaq Continued Listing Requirements
Filing view
External links